AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01036048 — intervention group
Intervention type: DEVICE
Intervention: bare metal stent
Description: pts with cabg disease treated with bare metal stent
Study NCT04587661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: off-the-shelf digital CBT
Description: Cognitive behavioral therapy for depression and anxiety
Study NCT04587661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted digital CBT
Description: Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
Study NCT00847210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
Study NCT00847210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
Study NCT03005158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validation Phase
Description: Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
Study NCT03005158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Randomization Phase
Description: Standard care or HighSTEACS pathway.
Study NCT03005158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Phase
Description: Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
Study NCT03798769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Description: Entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
Study NCT00867672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
Study NCT00867672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA
Description: VPA starting on day 6 of first cycle continuously throughout all treatment cycles
Study NCT00867672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
Study NCT00903188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop
Study NCT00903188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60.
Study NCT03846206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
Study NCT00663091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophage
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study NCT00663091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPP-201 Bacteriophage
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study NCT00663091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophages
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study NCT01850654 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: LS tumor screening
Description: All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
Study NCT01850654 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~* CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~* CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~* CRC study participants diagnosed with CRC \<50 years, regardless of tumor studies or family history~* CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing.
Study NCT01850654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Genetic Counseling
Description: The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling.
Study NCT01850654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biorepository
Description: The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
Study NCT01850654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Study NCT02622282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
Study NCT02622282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
Study NCT02622282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Handout includes information specific to participant's condition and ways to promote an active lifestyle.
Study NCT02622282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout
Description: Handout includes information specific to participant's condition and ways to promote an active lifestyle.
Study NCT01673737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR260301
Description: Pharmaceutical form: film-coated tablets Route of administration: oral
Study NCT01673737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Pharmaceutical form: film-coated tablets Route of administration: oral
Study NCT00561509 — intervention group
Intervention type: DRUG
Intervention: SSRIs
Description: Use within normal clinical practice
Study NCT00561509 — intervention group
Intervention type: DRUG
Intervention: Dual antidepressants
Description: Use within clinical practice
Study NCT01388335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Administered orally
Study NCT01388335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dypirone
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dypirone
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
Study NCT04148846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine block
Description: The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300 mg 8 / 8h for 7 days orally
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300 mg 8 / 8h for 7 days orally
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 4mg 8 / 8h for 48h orally
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4mg 8 / 8h for 48h orally
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline 200mg, 12 / 12h, for 5 days, orally
Study NCT04148846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 200mg, 12 / 12h, for 5 days, orally
Study NCT04148846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Espresso coffee
Description: Espresso coffee 20ml, 5x / day, for 7 days
Study NCT04148846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Espresso coffee
Description: Espresso coffee 20ml, 5x / day, for 7 days
Study NCT01288261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01288261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: Given IV
Study NCT01288261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01288261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study NCT02983552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad®
Description: Binocular therapy using a Dig Rush application on an iPad®
Study NCT02983552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle correction
Description: Spectacle correction for all waking hours, 7 days per week
Study NCT00623142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: 100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Study NCT02869568 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT02501577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAD 1
Description: Placement and fiberoptic control
Study NCT02501577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAD 2
Description: Placement and fiberoptic control
Study NCT01917630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALV003
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
Study NCT01917630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03532204 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered
Study NCT03532204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: At investigator's discretion
Study NCT03532204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: At investigator's discretion
Study NCT04411732 — intervention group
Intervention type: DEVICE
Intervention: MyotonPro
Description: Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
Study NCT04411732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute walk test
Description: The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
Study NCT04411732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semiquantitative muscle ultrasound
Description: Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
Study NCT04411732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand-held Dynamometry of muscle strength
Description: Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
Study NCT03126513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-POEM
Description: After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
Study NCT05539898 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation
Description: All included in the study will undergo ICD implantation for primary prevention of SCD
Study NCT04542317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH VN
Description: 4-6 sessions delivered over the course of 2-3 months.
Study NCT04542317 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced control
Description: A single session providing education about dementia
Study NCT03963258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration training
Description: The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
Study NCT03963258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional upper limb training
Description: compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
Study NCT01526733 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Study NCT01526733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20
Study NCT01526733 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Insulin aspart
Study NCT01526733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study NCT01526733 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Insulin lispro
Study NCT01526733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro